ITM Isotopen Technologien München AG
About ITM Isotopen Technologien München AG
ITM Isotopen Technologien München AG is a privately held group of companies dedicated to the development, production and global supply of innovative diagnostic and therapeutic radionuclides and radiopharmaceuticals. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class radionuclides and -generator platform for a new generation of targeted cancer diagnostics and therapies.
CEO: Steffen Schuster
CFO: Thomas Dürre
19 articles with ITM Isotopen Technologien München AG
ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. Market
ITM Isotopen Technologien München AG and RadioMedix Inc. announced that ITM has filed a Drug Master File with the U.S. Food and Drug Administration for ITM’s next generation Germanium-68/Gallium-68 Generator, which is manufactured at the RadioMedix Spica Center in Houston, Texas, U.S. and distributed under the brand name GeGant®.
ITM’s subsidiary ITG Isotope Technologies Garching GmbH to be incorporated by name under the ITM family brand
Future-oriented and long-term alliance with Endocyte for the further expansion of targeted radioligand therapy with no-carrier-added Lutetium-177 for prostate cancer patients
ITM and CIRC Sign Technology License Agreement for the Production and Distribution of Medical Radioisotopes in China
ITM Isotopen Technologien München AG and Chengdu Gaotong Isotope Co., Ltd. announced that they have signed a technology license agreement for the production and distribution of ITM Germanium-68/Gallium-68 Generators and no-carrier-added Lutetium-177 in China.
Bruce Power, ITM and Partners Finalize Agreement Paving Way for New Medical Isotope Delivery System Expected in 2022
Two partnership agreements signed will lay the groundwork for a new isotope delivery system at Bruce Power that will help provide lifesaving medical isotopes worldwide.
Nordic Nanovector Signs Global Clinical and Commercial Agreement With ITM for the Supply of No-carrier-added Lutetium-177
Nordic Nanovector ASA announces that it has signed a long-term global supply agreement with a subsidiary of ITM Isotopen Technologien München AG, Isotope Technologies Garching GmbH to ensure the supply of high quality, no-carrier-added Lutetium-177, a key component of Betalutin® for R&D, clinical and commercial uses.
ITM Isotopen Technologien München AG announced that ITM´s subsidiary, ITG Isotope Technologies Garching GmbH and Nordic Nanovector ASA have signed long-term global supply agreements for the medical radioisotope no-carrier-added Lutetium-177 EndolucinBeta® to support R&D, clinical and commercial supply of Betalutin®.
Key requirements met to start Ytterbium-176 irradiation at Bruce Power’s facilities for the production of ITM´s no-carrier-added Lutetium-177 for cancer therapy
This pivotal study is central to ITM’s global strategy of providing cutting edge radiotheranostic care to patients with neuroendocrine tumors.
ITM and DCB Sign Exclusive Licensing & Development Agreement for Solucin® TRT in South Korea while COMPETE Clinical Trial Sees Strong Growth in Recruitment Numbers in the U.S.
ITM Isotopen Technologien München AG and DuChemBio Co, Ltd. announced the conclusion of an exclusive licensing and development agreement for Solucin® Targeted Radionuclide Therapy in South Korea.
ITM Isotopen Technologien München AG announced the lease of a new building in Neufahrn near Munich to increase the production capacity of no-carrier-added Lutetium-177 and high-purity Lutetium-177 containing radiopharmaceuticals.
ITM and United Imaging team up in strategic partnership to cover Chinese and global cancer imaging markets
ITM Isotopen Technologien München AG and United Imaging Healthcare Co., Ltd. announced that they have signed an agreement to collaborate in marketing and sales of ITM and UIH imaging and related products to clinical customers in China and worldwide.
After enduring a deluge from multiple hurricanes earlier this year, the Carolinas are about to be flooded with something else far more preferable – jobs. Pharma companies are hiring for hundreds of positions, according to reports.
RadioMedix Inc. and ITM Isotopen Technologien München (ITM) announced today that ITM’s subsidiary, Isotope Technologies Garching GmbH (ITG), and RadioMedix have signed a manufacturing and supply agreement for the production of the next generation of Ge-68/Ga-68
Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617
ITM: FDA Acceptance of IND to Advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S.
Isotopen Technologien München AG announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND) to advance its innovative radiopharmaceutical Solucin® (n.c.a. 177Lu-Edotreotide), into a phase III clinical trial in the U.S..
Dr Philip Harris is a distinguished clinical endocrinologist and general physician, with a strong academic background. He has an extensive international network of contacts in clinical endocrine oncology and academia as well as in industry.
ITM: Enrollment of First Gastroenteropancreatic-Neuroendocrine Tumor (GEP-NET) Patient in Europe for the COMPETE Phase III Clinical Trial With N.C.A.177Lu-Edotreotide (Solucin)
The study will be conducted predominantly in Europe, North America, South Africa and Australia. The first patient to be enrolled and treated was in Australia.
ITM’s Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE With n.c.a.177Lu-Edotreotide (Solucin) in Cancer Patients With GEP-NET
ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution.